# A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

> **NCT02247739** · PHASE2 · COMPLETED · sponsor: **Pharming Technologies B.V.** · enrollment: 32 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **BIOLOGICAL:** Recombinant human C1 inhibitor
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02247739
- **Lead sponsor:** Pharming Technologies B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-05
- **Final completion:** 2016-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02247739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02247739, "A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT02247739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*